158P Patient (pt) demographics, treatment patterns (tx) and hematologic (heme) toxicities among pts with HER2− advanced breast cancer (ABC) and BRCA1/2 mutation(s) (BRCA1/2mut): A multi-country real-world (RW) study

Journal article

Peer reviewed

R Mahtani, A Niyazov, K Lewis, M Last, A Rider, B Arondekar and M.P Lux

Annals of oncology, Vol.31, pp.S73-S73

2020-05

Metrics

9 Record Views

This output has contributed to the advancement of the following goals:

Source: InCites

Title: 158P Patient (pt) demographics, treatment patterns (tx) and hematologic (heme) toxicities among pts with HER2− advanced breast cancer (ABC) and BRCA1/2 mutation(s) (BRCA1/2mut): A multi-country real-world (RW) study
Creators: R Mahtani - Sylvester Cancer Center, University of Miami, Deerfield Beach, FL, USA
A Niyazov - Pfizer Inc., New York, NY, USA
K Lewis - Adelphi Real World, Cheshire, UK
M Last - Adelphi Real World, Cheshire, UK
A Rider - Adelphi Real World, Cheshire, UK
B Arondekar - Pfizer Inc., Collegeville, PA, USA
M.P Lux - Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen- und Kinderklinik St. Louise, Paderborn, Germany
Publication Details: Annals of oncology, Vol.31, pp.S73-S73
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031597774802976